Rademikibart IV for Acute Asthma and COPD Exacerbation
Starting soon · Phase 2
Conditions studied: Asthma Acute, COPD Exacerbation Acute
In brief
A Phase 2, open-label, single-arm trial to evaluate IV rademikibart as an add-on treatment for acute exacerbation in participants with asthma or COPD with type 2 inflammation
Key facts
- Study ID
- NCT07705737
- Run by
- Connect Biopharm LLC
- People needed
- 40
- Starts
- 2026-07-30
- Expected to finish
- 2027-01-01
- Last updated by the study team
- 2026-07-15
Who can join
Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Columbus Clinical Services, LLC — Miami, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.